"Receptors, Progesterone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.
| Descriptor ID |
D011980
|
| MeSH Number(s) |
D12.776.826.750.765
|
| Concept/Terms |
Receptors, Progesterone- Receptors, Progesterone
- Progesterone Receptor
- Receptor, Progesterone
- Progestin Receptors
- Receptors, Progestin
- Progesterone Receptors
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Progesterone".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Progesterone".
This graph shows the total number of publications written about "Receptors, Progesterone" by people in this website by year, and whether "Receptors, Progesterone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 1 | 2 | 3 |
| 2002 | 0 | 3 | 3 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 2 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 2 | 3 | 5 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 4 | 6 |
| 2011 | 1 | 5 | 6 |
| 2012 | 0 | 6 | 6 |
| 2013 | 1 | 5 | 6 |
| 2014 | 4 | 4 | 8 |
| 2015 | 2 | 3 | 5 |
| 2016 | 3 | 4 | 7 |
| 2017 | 2 | 5 | 7 |
| 2018 | 2 | 6 | 8 |
| 2019 | 5 | 3 | 8 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 1 | 2 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Progesterone" by people in Profiles.
-
Machine Learning-Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2- Early Breast Cancer Using Real-World and NATALEE Data. Clin Cancer Res. 2026 Jan 16; 32(2):428-437.
-
Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER Trial. JAMA Netw Open. 2025 Dec 01; 8(12):e2549109.
-
Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer. Ann Oncol. 2025 Nov; 36(11):1356-1365.
-
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer. Expert Rev Anticancer Ther. 2025 Jun; 25(6):675-686.
-
Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers. Clin Cancer Res. 2025 Jan 17; 31(2):403-413.
-
ASO Author Reflections: Breast-Conserving Surgery After Neoadjuvant Systemic Therapy for Early-Stage Breast Cancer: Quantitative Biomarkers and Disparities in the Precision-Medicine Era. Ann Surg Oncol. 2024 Dec; 31(13):8904-8905.
-
Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer. Ann Surg Oncol. 2024 Dec; 31(13):8829-8842.
-
Placental histology for targeted risk assessment of recurrent spontaneous preterm birth. Am J Obstet Gynecol. 2024 04; 230(4):452.e1-452.e11.
-
Progesterone Signaling and Uterine Fibroid Pathogenesis; Molecular Mechanisms and Potential Therapeutics. Cells. 2023 04 09; 12(8).
-
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022 06 13; 40(6):609-623.e6.